Coya Therapeutics Inc (COYA)
$6.4
+0.44
(+7.38%)▲
Market is closed - opens 7 PM, 16 Sep 2024
Performance
- $5.92$6.40$6.40
7.5%
Downside
Day's Volatility :7.5%
Upside
0.0%
- $3.21$10.69$6.40
49.84%
Downside
52 Weeks Volatility :69.97%
Upside
40.13%
Returns
| Period | Coya Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -11.11% | 0.0% |
6 Months | -36.0% | 0.0% |
1 Year | 38.53% | 0.0% |
3 Years | 40.04% | -20.0% |
Highlights
Market Capitalization | 90.7M |
Book Value | $2.32 |
Earnings Per Share (EPS) | -0.74 |
Wall Street Target Price | 14.83 |
Profit Margin | -105.71% |
Operating Margin TTM | -94.48% |
Return On Assets TTM | -23.55% |
Return On Equity TTM | -41.64% |
Revenue TTM | 9.6M |
Revenue Per Share TTM | 0.76 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -10.2M |
Diluted Eps TTM | -0.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.3 |
EPS Estimate Next Year | -1.38 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.43 |
Analyst Recommendation
Buy
87%Buy
12%Hold
0
0%Sell
Based on 8 Wall street analysts offering stock ratings for Coya Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
- Current
- 1M Ago
- 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 131.72%
Current $6.40
Target $14.83
Technicals Summary
Sell
Neutral
Buy
Coya Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Coya Therapeutics Inc | 32.92% | -36.0% | 38.53% | 40.04% | 40.04% |
 Regeneron Pharmaceuticals, Inc. | -0.3% | 20.26% | 38.56% | 78.77% | 303.42% |
 Novo Nordisk A/s | 1.92% | 1.8% | 42.06% | 173.92% | 453.76% |
 Alnylam Pharmaceuticals, Inc. | 0.91% | 78.6% | 37.4% | 41.12% | 212.93% |
 Vertex Pharmaceuticals Incorporated | 2.95% | 18.74% | 38.91% | 157.61% | 173.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Coya Therapeutics Inc | NA | NA | NA | -1.3 | -0.42 | -0.24 | NA | 2.32 |
Regeneron Pharmaceuticals, Inc. | 30.86 | 30.86 | 1.59 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.01 | 46.01 | 2.08 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Coya Therapeutics Inc | Buy | $90.7M | 40.04% | NA | -105.71% |
Regeneron Pharmaceuticals, Inc. | Buy | $128.4B | 303.42% | 30.86 | 32.04% |
Novo Nordisk A/s | Buy | $600.4B | 453.76% | 46.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 212.93% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.3B | 173.37% | 32.84 | -4.74% |
Insights on Coya Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 3.6%
Company Information
Organization | Coya Therapeutics Inc |
Employees | 8 |
CEO | Dr. Howard Berman Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$6.40
+7.38%
Keyarch Acquisition Corp
$6.40
+7.38%
Connexa Sports Technologies Inc
$6.40
+7.38%
Us Value Etf
$6.40
+7.38%
First Wave Biopharma Inc
$6.40
+7.38%
Global X Msci Next Emerging
$6.40
+7.38%
Fat Projects Acquisition Corp
$6.40
+7.38%
Capital Link Global Fintech
$6.40
+7.38%
Applied Uv Inc
$6.40
+7.38%